血管瘤与脉管畸形诊疗现状与展望

doi:10.35541/cjd.20200603

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (7): 501-507.doi: 10.35541/cjd.20200603

血管瘤与脉管畸形诊疗现状与展望

李丽,张斌,尉莉,马琳

国家儿童医学中心首都医科大学附属北京儿童医院皮肤科 100045

收稿日期:2020-06-15 修回日期:2020-06-18 发布日期:2020-07-06
通讯作者: 马琳 E-mail:bch_maleen@aliyun.com

Diagnosis and treatment of hemangiomas and vascular malformations: current status and prospect

Li Li,Zhang Bin ,Wei Li ,Ma Lin

Department of Dermatology, Beijing Children′s Hospital, Capital Medical University, National Center for Children′s Health, Beijing 100045, China

Received:2020-06-15 Revised:2020-06-18 Published:2020-07-06
Contact: Ma Lin E-mail:bch_maleen@aliyun.com

摘要/Abstract

摘要： 【摘要】随着血管瘤和脉管畸形分类的不断更新，其诊断和治疗也逐步发展。婴儿血管瘤预后良好，但治疗时机和方法选择对预后至关重要，β受体阻滞剂是一线药物。而脉管畸形尤其一些发病率较低的脉管畸形相关综合征的正确诊断及鉴别诊断仍是现代医学领域面临的挑战。近年研究显示，脉管畸形致病与相关基因突变相关，这些发现为靶向药物治疗提供了理论依据。本文阐述常见的血管瘤及脉管畸形的诊断和治疗现状、存在问题及未来研究方向。

关键词: 血管瘤, 血管畸形, 淋巴管畸形, 诊断, 治疗

Abstract: 【Abstract】 Hemangiomas and vascular malformations are common diseases in children. With the continuous update of disease classification criteria, their diagnosis and treatment have also gradually developed. Infantile hemangioma has a good prognosis, but the timing and method of treatment are crucial to the prognosis. Beta-blockers are the first-line drugs for the treatment of infantile hemangioma. The correct diagnosis and differential diagnosis of vascular malformations, especially some vascular malformation-related syndromes with low incidence, are still challenges in the field of modern medicine. Recent studies have shown that the pathogenesis of vascular malformations is associated with mutations in related genes, which provides a theoretical basis for targeted drug therapy. Multidisciplinary integration is the future trend in the diagnosis and treatment of vascular malformations. This review describes the current status of, as well as problems and future research directions in the diagnosis and treatment of common hemangiomas and vascular malformations.

Key words: Hemangioma, Vascular malformations, Lymphatic abnormalities, Diagnosis, Therapy

李丽张斌尉莉马琳. 血管瘤与脉管畸形诊疗现状与展望[J]. 中华皮肤科杂志, 2020,53(7):501-507. doi:10.35541/cjd.20200603

Li Li Zhang Bin Wei Li Ma Lin. Diagnosis and treatment of hemangiomas and vascular malformations: current status and prospect[J]. Chinese Journal of Dermatology, 2020, 53(7): 501-507.doi:10.35541/cjd.20200603

参考文献 44

［1］	Munden A, Butschek R, Tom WL, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies［J］. Br J Dermatol, 2014,170（4）:907⁃913. doi: 10.1111/bjd.12804.
［2］	Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature［J］. Pediatr Dermatol, 2008,25（2）:168⁃173. doi: 10.1111/j.1525⁃1470.2008. 00626.x.
［3］	Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics［J］. Plast Reconstr Surg, 1982,69（3）:412⁃422. doi: 10.1097/00006534⁃198203000⁃00002.
［4］	Enjolras O. Classification and management of the various superficial vascular anomalies: hemangiomas and vascular malformations［J］. J Dermatol, 1997,24（11）:701⁃710. doi: 10. 1111/j.1346⁃8138.1997.tb02522.x.
［5］	Dasgupta R, Fishman SJ. ISSVA classification［J］. Semin Pediatr Surg, 2014,23（4）:158⁃161. doi: 10.1053/j.sempedsurg. 2014.06.016.
［6］	Léauté⁃Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy［J］. N Engl J Med, 2008,358（24）:2649⁃2651. doi: 10.1056/NEJMc0708819.
［7］	Barnés CM, Christison⁃Lagay EA, Folkman J. The placenta theory and the origin of infantile hemangioma［J］. Lymphat Res Biol, 2007,5（4）:245⁃255. doi: 10.1089/lrb.2007.1018.
［8］	Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex［J］. Arch Dermatol, 2002,138（12）:1567⁃1576. doi: 10.1001/archderm.138.12.1567.
［9］	Reimer A, Fliesser M, Hoeger PH. Anatomical patterns of infantile hemangioma （IH） of the extremities （IHE）［J］. J Am Acad Dermatol, 2016,75（3）:556⁃563. doi: 10.1016/j.jaad.2016. 03.029.
［10］	Yeh I, Bruckner AL, Sanchez R, et al. Diffuse infantile hepatic hemangiomas: a report of four cases successfully managed with medical therapy［J］. Pediatr Dermatol, 2011,28（3）:267⁃275. doi: 10.1111/j.1525⁃1470.2011.01421.x.
［11］	Metry D, Heyer G, Hess C, et al. Consensus statement on diagnostic criteria for PHACE syndrome［J］. Pediatrics, 2009,124（5）:1447⁃1456. doi: 10.1542/peds.2009⁃0082.
［12］	Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies［J］. J Pediatr, 2010,157（5）:795⁃801.e1⁃7. doi: 10.1016/j.jpeds.2010.05.027.
［13］	中华医学会皮肤性病学分会儿童学组，中华医学会儿科学分会皮肤性病学组，中国医师协会皮肤科医师分会儿童皮肤病专业委员会，等. β受体阻滞剂治疗婴儿血管瘤中国专家共识［J］.中华皮肤科杂志, 2020,53（7）:493⁃500. doi: 10.35541/cjd.20200302.
［14］	Nasseri E, Piram M, McCuaig CC, et al. Partially involuting congenital hemangiomas: a report of 8 cases and review of the literature［J］. J Am Acad Dermatol, 2014,70（1）:75⁃79. doi: 10.1016/j.jaad.2013.09.018.
［15］	Boon LM, Enjolras O, Mulliken JB. Congenital hemangioma: evidence of accelerated involution［J］. J Pediatr, 1996,128（3）:329⁃335. doi: 10.1016/s0022⁃3476（96）70276⁃7.
［16］	Enjolras O, Mulliken JB, Boon LM, et al. Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly［J］. Plast Reconstr Surg, 2001,107（7）:1647⁃1654. doi: 10.1097/0000 6534⁃200106000⁃00002.
［17］	Roebuck D, Sebire N, Lehmann E, et al. Rapidly involuting congenital haemangioma （RICH） of the liver［J］. Pediatr Radiol, 2012,42（3）:308⁃314. doi: 10.1007/s00247⁃011⁃2268⁃z.
［18］	Ozcan UA. Rapidly involuting congenital hemangioma: a case of complete prenatal involution［J］. J Clin Ultrasound, 2010,38（2）:85⁃88. doi: 10.1002/jcu.20647.
［19］	Weitz NA, Lauren CT, Starc TJ, et al. Congenital cutaneous hemangioma causing cardiac failure: a case report and review of the literature［J］. Pediatr Dermatol, 2013,30（6）:e180⁃e190. doi: 10.1111/j.1525⁃1470.2012.01875.x.
［20］	Ji Y, Chen S, Yang K, et al. Kaposiform hemangioendothelioma: current knowledge and future perspectives［J］. Orphanet J Rare Dis, 2020,15（1）:39. doi: 10.1186/s13023⁃020⁃1320⁃1.
［21］	Putra J, Gupta A. Kaposiform haemangioendothelioma: a review with emphasis on histological differential diagnosis［J］. Pathology, 2017,49（4）:356⁃362. doi: 10.1016/j.pathol.2017.03. 001.
［22］	Mahajan P, Margolin J, Iacobas I. Kasabach⁃Merritt phenomenon: classic presentation and management options［J］. Clin Med Insights Blood Disord, 2017,10:1179545X17699849. doi: 10.1177/1179545X17699849.
［23］	Johnson AB, Richter GT. Vascular anomalies［J］. Clin Perinatol, 2018,45（4）:737⁃749. doi: 10.1016/j.clp.2018.07.010.
［24］	Hall GW. Kasabach⁃Merritt syndrome: pathogenesis and management［J］. Br J Haematol, 2001,112（4）:851⁃862. doi: 10. 1046/j.1365⁃2141.2001.02453.x.
［25］	O′Rafferty C, O′Regan GM, Irvine AD, et al. Recent advances in the pathobiology and management of Kasabach⁃Merritt phenomenon［J］. Br J Haematol, 2015,171（1）:38⁃51. doi: 10. 1111/bjh.13557.
［26］	Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach⁃Merritt phenomenon in 107 referrals［J］. J Pediatr, 2013,162（1）:142⁃147. doi: 10.1016/j.jpeds.2012.06.044.
［27］	Drolet BA, Trenor CC 3rd, Brandão LR, et al. Consensus⁃derived practice standards plan for complicated Kaposiform hemangioendothelioma［J］. J Pediatr, 2013,163（1）:285⁃291. doi: 10.1016/j.jpeds.2013.03.080.
［28］	Peng S, Yang K, Xu Z, et al. Vincristine and sirolimus in the treatment of kaposiform haemangioendothelioma［J］. J Paediatr Child Health, 2019,55（9）:1119⁃1124. doi: 10.1111/jpc.14370.
［29］	Schmid I, Klenk AK, Sparber⁃Sauer M, et al. Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options［J］. World J Pediatr, 2018,14（4）:322⁃329. doi: 10.1007/s12519⁃018⁃0171⁃5.
［30］	中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南（2019版）［J］. 组织工程与重建外科杂志, 2019,15（5）:277⁃317. doi: 10.3969/j.issn.1673⁃0364.2019.05.001.
［31］	Shirley MD, Tang H, Gallione CJ, et al. Sturge⁃Weber syndrome and port⁃wine stains caused by somatic mutation in GNAQ［J］. N Engl J Med, 2013,368（21）:1971⁃1979. doi: 10.1056/NEJMoa 1213507.
［32］	Tatton⁃Brown K, Weksberg R. Molecular mechanisms of childhood overgrowth［J］. Am J Med Genet C Semin Med Genet, 2013,163C（2）:71⁃75. doi: 10.1002/ajmg.c.31362.
［33］	Rodriguez⁃Laguna L, Ibañez K, Gordo G, et al. CLAPO syndrome: identification of somatic activating PIK3CA mutations and delineation of the natural history and phenotype［J］. Genet Med, 2018,20（8）:882⁃889. doi: 10.1038/gim.2017.200.
［34］	Nguyen D, Turner JT, Olsen C, et al. Cutaneous manifestations of proteus syndrome: correlations with general clinical severity［J］. Arch Dermatol, 2004,140（8）:947⁃953. doi: 10.1001/archderm.140.8.947.
［35］	Wouters V, Limaye N, Uebelhoer M, et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper⁃phosphorylating effects［J］. Eur J Hum Genet, 2010,18（4）:414⁃420. doi: 10.1038/ejhg. 2009.193.
［36］	Limaye N, Kangas J, Mendola A, et al. Somatic activating PIK3CA mutations cause venous malformation［J］. Am J Hum Genet, 2015,97（6）:914⁃921. doi: 10.1016/j.ajhg.2015.11.011.
［37］	Özgönenel B, Martin A. Low⁃dose sirolimus controls recurrent iron deficiency in a patient with blue rubber bleb nevus syndrome［J］. Pediatr Blood Cancer, 2015,62（11）:2054⁃2055. doi: 10.1002/pbc.25590.
［38］	张斌, 李丽, 尉莉, 等. 口服西罗莫司治疗儿童复杂性静脉畸形的效果和安全性: 一项单中心前瞻性研究［J］. 中华整形外科杂志, 2020,36（5）:483⁃493. doi: 10.3760/cma.j.cn114453⁃20200315⁃00152.
［39］	Zhang B, Li L, Zhang N, et al. Efficacy and safety of sirolimus in the treatment of blue rubber bleb naevus syndrome in paediatric patients［J］. Clin Exp Dermatol, 2020,45（1）:79⁃85. doi: 10. 1111/ced.14003.
［40］	Luks VL, Kamitaki N, Vivero MP, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA［J］. J Pediatr, 2015,166（4）:1048⁃1054.e1⁃5. doi: 10.1016/j.jpeds.2014.12.069.
［41］	Ivars M, Redondo P. Efficacy of topical sirolimus （rapamycin） for the treatment of microcystic lymphatic malformations［J］. JAMA Dermatol, 2017,153（1）:103⁃105. doi: 10.1001/jamadermatol.2016.3697.
［42］	Shoji MK, Shishido S, Freitag SK. The use of sirolimus for treatment of orbital lymphatic malformations: a systematic review［J］. Ophthalmic Plast Reconstr Surg, 2020,36（3）:215⁃221. doi: 10.1097/IOP.0000000000001518.
［43］	Burrows PE, Mulliken JB, Fishman SJ, et al. Pharmacological treatment of a diffuse arteriovenous malformation of the upper extremity in a child［J］. J Craniofac Surg, 2009,20 Suppl 1:597⁃602. doi: 10.1097/SCS.0b013e3181927f1e.
［44］	Lekwuttikarn R, Lim YH, Admani S, et al. Genotype⁃guided medical treatment of an arteriovenous malformation in a child［J］. JAMA Dermatol, 2019,155（2）:256⁃257. doi: 10.1001/jamadermatol.2018.4653.

[1]	孙小洁刘毅. 抗雄激素药物治疗皮肤病研究进展[J]. 中华皮肤科杂志, 2023, 56(9): 882-885.
[2]	王钰倩乔建军方红. 国内外斑秃诊疗指南/共识比较 [J]. 中华皮肤科杂志, 2023, 56(9): 885-888.
[3]	刘元香梁源赵欣荣孙玉娟马琳徐子刚. JAK抑制剂治疗儿童重症斑秃5例[J]. 中华皮肤科杂志, 2023, 56(9): 849-852.
[4]	王俊霞郭伟楠陈慧郝军峰李冰卫静宜赵涛. 自体脂肪移植治疗40例稳定期线状硬斑病疗效回顾分析[J]. 中华皮肤科杂志, 2023, 56(8): 762-765.
[5]	陈小敏张景展丁媛康晓静. 二甲双胍治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(8): 799-802.
[6]	周彤耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793.
[7]	袁心刚倪思利张建罗晓燕王华. 儿童黑素细胞痣的诊疗水平亟待提高[J]. 中华皮肤科杂志, 2023, 56(8): 782-786.
[8]	钟洁敏邵蕾梁毅敏黄琼霄夏曼琪刘玉梅. 射频火针与光动力疗法治疗面部中重度痤疮炎性皮损的疗效与安全性对比研究[J]. 中华皮肤科杂志, 2023, 56(8): 751-755.
[9]	宋志强陈奇权葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723.
[10]	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）[J]. 中华皮肤科杂志, 2023, 56(7): 573-625.
[11]	李越吴金燕袁若月杨屈杨赵贤省朱宁文. 细胞治疗遗传性大疱性表皮松解症研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 698-702.
[12]	陈奇权杨显杰顾恒徐金华郝飞姚煦宋志强. [开放获取] 基于德尔菲法构建《中国慢性诱导性荨麻疹诊治专家共识（2023）》[J]. 中华皮肤科杂志, 2023, 56(6): 534-539.
[13]	中华医学会皮肤性病学分会免疫学组. [开放获取] 中国慢性诱导性荨麻疹诊治专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 479-488.
[14]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 489-495.
[15]	米淑宏余艳琴郝金奇李薇张杨贾喜梅黄毓娴孙怀玉石继海. 丘疹脓疱型玫瑰痤疮患者皮肤高频超声联合彩色多普勒血流成像的特征[J]. 中华皮肤科杂志, 2023, 56(6): 540-544.

血管瘤与脉管畸形诊疗现状与展望

Diagnosis and treatment of hemangiomas and vascular malformations: current status and prospect

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 44

相关文章 15

Metrics

本文评价

推荐阅读 10